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ABSTRACT Bioscavengers are biopharmaceuticals that specifically react with toxicants.  thus, enzymes reacting with poisonous esters can be used as 
bioscavengers for neutralization of toxic molecules before they reach physiological targets.  Parenteral administration of bioscavengers is, therefore, intended 
for prophylaxis or pre-treatments, emergency and post-exposure treatments of intoxications.  these enzymes can also be used for application on skin, mucosa 
and wounds as active components of topical skin protectants and decontamination solutions. 
Human butyrylcholinesterase is the first stoichiometric bioscavenger for safe and efficient prophylaxis of organophosphate poisoning. However, huge amounts 
of a costly enzyme are needed for protection. thus, the bioscavenger approach will be greatly improved by the use of catalytic bioscavengers. catalytic bioscav-
engers are enzymes capable of degrading toxic esters with a turnover. 
Suitable catalytic bioscavengers are engineered mutants of human enzymes. efficient mutants of human butyrylcholinesterase have been made that hydrolyze 
cocaine at a high rate.  Mutants of human cholinesterases capable of hydrolyzing OPs have been made, but so far their activity is too low to be of medical inter-
est.  Human paraoxonase a promiscuous plasma enzyme is certainly the most promising phosphotriesterase. However, its biotechnology is still in its infancy. 
Other enzymes and proteins from blood and organs, and secondary biological targets of OPs and carbamates are potential bioscavengers, in particular serum 
albumin that reacts with OPs and self-reactivates. Lastly, non-human enzymes, phosphotriesterases and oxidases from various bacterial and eukaryotic sources 
could be used for external use against OP poisoning and for internal use after modifications for immunological compatibility. 
Key-words: bioscavengers, carbamates, cocaine, enzyme engineering, enzymotherapy, organophosphorus compounds
Abbreviations: Ache, acetylcholinesterase; Bche, butyrylcholinesterase; cae, carboxylesterase; che, cholinesterase; DFPase, diisopropylfluorophosphate 
hydrolase; GMP, good manufacturing practice; GMP, good manufacturing practice, GSt, glutathione S-transferase; OP, organophosphorus compound; OPAA, 
organophosphoric acid anhydrolase; OPAH, organophosphorus acid anhydride hydrolase; PeG, polyethylene glycol; POn1, paraoxonase 1; Pte, phosphotrieste-
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1 . THE BIOSCAVENGER CONCEPT
enzyme systems located in skin, blood organs are involved in 
natural defences against endogenous and exogenous poisons. 
Detoxification processes occur through different types of re-
actions, including oxidation, hydrolysis, and conjugation. the 
role of liver, lung and kidney enzymes, cytochromes P450 
(Brown et al., 2008), oxidases, transferases (Miners et al., 
2006), amido-carboxylesterases (redinbo and Potter, 2005; 
Potter and Wadkins, 2006; Satoh and Hosokawa, 2006) in the 
metabolism of drugs and xenobiotics is well known. the im-
portance of plasma esterases in the inactivation of numerous 
toxicants has been recognized, too. Lastly, there is growing 
evidence that catalytic antibodies play also an efficient role 
in scavenging deleterious molecules and radicals (Belogurov 
et al., 2009). these multiple enzymes constitute cellular and 
circulating barriers that protect physiological machineries reVIeWS
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and systems against specific toxicants. Here we will examine 
endogenous and exogenous enzymes that react with poison-
ous carboxylic-, organophosphoryl- and carbamyl-esters. 
these enzymes act either as stoichiometric bioscavengers 
or catalytic bioscavengers. catalytic bioscavengers are bio-
catalysts capable of degrading poisonous compounds with a 
turnover. enzymes that are potential catalytic bioscavengers 
will be reviewed. 
After a short survey of catalytic bioscavengers against 
cocaine, we will focus on biocatalysts to be used for proph-
ylaxis and treatment of organophosphate poisoning.  In-
deed, OP poisoning is a major public-health problem. OP 
self-poisoning is responsible for 200,000 deaths a year in 
the world (eddelston et al., 2008). In addition, though 185 
nations have joined the chemical Weapons convention 
(cWc), nerve agents and other organophosphorus com-
pounds still represent military and terrorist threats. Sig-
nificant progress has been made in the past twenty years 
in countermeasures of OP poisoning (Aas, 2003; Albu-
querque et al., 2006; Wetherell et al., 2007; eyer et al., 2007; 
thiermann et al., 2007). However, classical pharmacologi-
cal approaches have reached their optimum limit. toxicity 
of OPs can be countered by reducing skin absorption and 
lowering OP concentration in the blood compartment, thus 
preventing the transfer of OP molecules towards physi-
ological targets (Fig. 1). neutralization of OPs has proved to 
be possible by using stoichiometric traps, first generation 
bioscavengers. the catalytic bioscavenger concept, second 
generation bioscavengers, is based on the idea of continu-
ously trapping and degrading OPs in the blood stream be-
fore OP molecules reach their central and peripheral neu-
ronal and neuromuscular targets.
2 . DETOxIFICATION OF (-)COCAINE
unlike the plasma of most mammalians, there is no car-
boxylesterase in human plasma (Li et al., 2005). However, 
two enzymes are capable of degrading esters in the blood 
stream. Plasma paraoxonase (POn1; ec 3.1.8.1) displays an 
arylesterase activity, and butyrylcholinesterase (Bche; ec 
3.1.1.8) — that has broad esterase specificity — plays a role 
in processing, catabolism and or detoxification of numer-
ous poisonous esters: for instance, human Bche hydrolyzes 
ester-containing therapeutic and/or addictive drugs such 
as succinylcholine and its long-chain derivatives (Grigory-
an et al., 2008), aspirin, irinotecan, heroin (Lockridge, 1990; 
Li et al., 2005). Plasma Bche also hydrolyzes prodrugs such 
as isosorbide diaspirinate, bambuterol (Li et al., 2005), and 
ISDA, a new aspirin prodrug (Moriarty et al., 2008). 
Plasma Bche is the major detoxifying enzyme of cocaine 
in humans (Inaba et al., 1978) and has been demonstrated 
to efficiently protect animals against cocaine toxicity (Hoff-
man et al., 1996; Lynch et al., 1997).  However, Bche slowly 
hydrolyzes (-)cocaine with kcat/Km about 0.28 µM-1.min-1, 
so that under physiological conditions, a large part of the 
administered dose of cocaine reaches biological targets and 
triggers toxic effects. Mutagenesis efforts pursued over the 
last decade have dramatically enhanced the cocaine hy-
drolase activity of human Bche. A first mutation, A328Y, 
enhanced the catalytic efficiency 4-fold (Xie et al., 1999). 
Molecular dynamics simulation and computer-based lig-
and docking led to the A328W/Y332A double mutant that 
displays a higher kcat/Km=8.5 µM-1.min-1 (Sun et al., 2002). 
Further mutations using random mutagenesis raised kcat/
Km. the simulation of activation transition state approach 
was also successfully applied to the design of new Bche 
mutants. using the three-dimensional structure of human 
Bche (nicolet et al., 2003), molecular dynamic simula-
tions of the deacylation transition state led to the design of 
highly active mutants against (-)cocaine. this was achieved 
by combining four mutations, A199S/S287G/A328W/
Y332G, and yielded an enzyme with a catalytic efficiency 
456-fold greater than that of wild-type Buche (Pan et al., 
2005; Zheng and Zhan, 2008). the efficient quadruple mu-
tant was fused to human albumin to improve its pharma-
cokinetics properties (t1/2=8h in plasma) without altering 
its catalytic efficiency (Brimijoin et al., 2008). At 10 mg/
kg, the fusion enzyme stopped the symptoms of cocaine 
intoxication in rats at a lethal dose (100 mg/kg, i.p.). In-
terestingly, it also blocked cocaine-induced reinstatement 
of drug-seeking in rats that had previously self-adminis-
tered cocaine. More recently, introduction of 5 mutations, 
A199S/F227A/S287G/A328W/Y332G, led to a more active 
enzyme (Zheng et al., 2008). therefore, the fusion enzyme 
and new mutants are promising for an efficient therapeutic 
approach to cocaine overdose rescue and the treatment of 
addiction. Immunopharmacotherapy for cocaine addition 
can be an alternative strategy. Monoclonal antibodies cata-
lyzing the hydrolysis of (-)cocaine have been made (Landry 
et al., 1993; Larsen et al., 2004; McKenzie et al., 2007). How-
ever, the kinetic parameters of catalytic antibodies have to 
be improved. computational (transition state simulations, 
free energy barrier shift calculations) and mutagenesis ap-
proaches are expected to lead to more efficient biocatalysts 
(Pan et al., 2008).
3 . DETOxIFICATION OF ORGANOPHOSPHORuS COMPOuNDS
Organophosphates are widely used as pesticides.  Some 
OPs are drugs, others are potent chemical warfare agents. 
OPs are irreversible inhibitors of cholinesterases (ches): 
acetylcholinesterase (Ache; ec 3.1.1.7) and butyrylcho-
linesterase (Fig. 2).  Ache plays a major role in the cholin-
ergic system terminating the action of acetylcholine. thus, 
synaptic Aches are the primary targets of OPs. Irrevers-
ible inhibition of Ache is the main cause of acute toxicity 
of OPs (Maxwell et al., 2006). no clear physiological func-
tion has been ascribed to Bche. In the nervous system and 
at neuromuscular junctions, Bche may surrogate Ache 
under certain conditions (Lockridge et al., 2009). However, 
Bche is of pharmacological and toxicological importance as 
shown in the previous section.
endogenous enzymes are involved in natural defences 
against OP toxicity.  the presence of OP detoxifying en-
zymes in skin contributes to reduce the amount of OP that 
penetrates into the body (Schallreuter et al., 2007). certain 
secondary targets of OPs found in various tissues are de-
toxifying enzymes, and they certainly play a role in the 
natural defences against OPs (Wang et al., 1998; nomura 
et al., 2005, 2008). natural blood bioscavengers significantly 
contribute to reduce the amount of OP molecules reaching 
physiological targets.  Bche is the most important stoichio-70 | ActA nAturAe |  № 1 2009
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metric OP scavenger in human plasma; its concentration is 
about 50 nM and its apparent second-order rate constant 
with OPs is ≈107 M-1 min-1.  Human plasma POn1 displays 
activities categorized as “accidental” or “promiscuous” 
(costa and Furlong, 2002; Mackness et al., 2008). Albeit its 
primary function is likely to be a lipophilic lactonase (Kher-
sonsky and tawfik 2005) involved in protection against 
atherosclerosis (Shih et al., 1998; Watson et al., 1995), it hy-
drolyzes numerous OPs.  It has been shown that animals 
in which the plasma concentration in POn1 is high are 
relatively resistant to OPs (Kaliste-Korhonen et al. 1996).   
conversely, knockout mice for POn1 are very sensitive to 
OPs (Shih et al., 1998).  Albumin displays a low esterase ac-
tivity and slowly reacts with carbamyl- and phosphoryl-
esters. However, its concentration in the blood and lymph 
is high (≈0.6 mM), and it appears to play a significant role 
in the detoxification of carbaryl  (Sogorb et al., 2007). Plas-
ma albumin could also play a role in detoxification of OPs 
(tarhoni et al., 2007; Li et al., 2008), even at toxicologically 
relevant concentrations (Sogorb et al., 2008).  
OPs are also neutralized by tissues (liver) carboxyleste-
rases (cae; ec 3.1.1.1) and oxidized by oxidases such as cy-
tochrome P450s, glutathione S-transferases, laccases, and 
peroxidases.  Glutathione S-transferases (GSt; ec 2.5.1.18) 
are 20-30kDa enzymes that catalyze glutathione conjuga-
tion (nucleophilic attack of the thiol group) to electrophilic 
substrates. these enzymes are involved in the cellular de-
toxification processes of endogenous compounds and of 
numerous xenobiotics, and their role in the resistance of 
insects to insecticides is well established. OP detoxification 
by GSts results from a regioselective dealkylation of the 
alkyl or aryl side chain (Maturano et al., 1997). there is evi-
dence that GSts contribute to OP detoxification in humans 
(Fujioka and casida, 2007).
4 . STOICHIOMETRIC BIOSCAVENGERS AGAINST OPS
Administration of human plasma has been used for treat-
ing OP poisoning. the effects of fresh frozen plasma on 
cholinesterase levels and outcomes in patients with OP-
poisoning were evaluated (Güven et al. 2004). results sug-
gest that plasma therapy may be an effective alternative or 
adjunctive treatment method.  Plasma Bche and possibly 
other abundant OP scavenging proteins in plasma (albumin 
and POn1) may have contributed to this result.
research on stoichiometric bioscavengers mostly focused 
on enzymes that specifically react with OPs; i.e. cholineste-
rases (Wolfe et al., 1987) and carboxylesterases (redindo 
and Potter, 2005; Fleming et al., 2007). Prophylactic injec-
tion of enzymes capable of inactivating OP quickly would 
allow first responders; i.e firemen, explosive ordnance dis-
posal technicians, and medical personnels to work safely in 
a contaminated environment.  Intravenous or intramuscular 
administration of bioscavengers to chemical casualties is ex-
pected to greatly improve the efficacy of implemented phar-
macological countermeasures (Ashani et al., 1998; Saxena et 
al., 2006). However, enzymatic stoichiometric neutralization 
of OP needs the administration of a huge amount of a costly 
bioscavenger, e.g., about 3 mg/kg of highly purified plasma 
Bche for challenging several LD50 of OP (Ashani and Pistin-
ner, 2004).  Large-scale production of enzymes under GMP 
conditions at a reasonable cost has been the subject of in-
tense research in north America. 
two industrial GMP processes exist for mass production 
of human Bche. the first one is purification of the natural 
enzyme from the cohn Fraction IV of human plasma. One 
liter of plasma provides less than one milligram of GMP 
Bche. this process has been developped by Baxter Health-
care corporation in the uSA (www.baxter.com). Highly 
purified human plasma Bche was granted the status of In-
vestigational new Drug by the Food and Drug Administra-
tion in 2006 for protection against nerve agents in the uSA 
(Lenz et al., 2007; Saxena et al., 2007). Phase I of clinical tri-
als on volunteers will be completed in Spring 2009, so that 
enzyme could be marketed soon. the second process has 
been developped by nexia in canada (www.nexiabiotech.
com). It uses the recombinant human enzyme produced in 
the milk of trangenic goats. Several grams of enzyme can 
Figure 1: Biological fate of organophosphorus compounds in humans. 
Routes of penetration of OPs are absorption through the skin, eyes, 
and/or respiratory tract (nerve agents, pesticides), or ingestion (self‑
poisoning). OP molecules distribute from the blood compartment into 
tissues, including depot sites, biophase (physiological targets), and sites 
of elimination (liver and kidneys). ChEs of cholinergic synapses are the 
primary targets; their inhibition is responsible for the acute toxicity of 
OPs; reaction with secondary targets (carboxylesterases, serine‑amidas‑
es, peptidases and other serine/tyrosine proteins) may be responsible 
for the non‑cholinergic sub‑lethal effects of OPs and chronic toxicity at 
low‑dose exposure (Casida and Quistad, 2004; Costa, 2006).reVIeWS
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be secreted in one liter of milk. this recombinant enzyme 
has been named ProtexiatM. Since 2005, the firm Phar-
matheme in Maryland, uSA (www.pharmathene.com), has 
been developping ProtexiatM, PeGylated derivatives of the 
recombinant enzyme (Huang et al., 2007) and fusion pro-
teins (Huang et al., 2008).
Secondary targets of OPs and other enzymes interact-
ing with OPs are potential stoichiometric bioscavengers.   
In particular, owing to the high number of amino acid 
residues in albumin that covalently bind OP molecules (5 
tyrosines and 2 serines) (Ding et al., 2008), the reactivity 
of tyrosine residues can be enhanced upon specific modi-
fication, e.g., nitration that causes a decrease in the pKa of 
tyrosine by several orders of magnitude (Masson et al., un-
published results). Modified human albumin could lead to 
a new generation of stoichiometric bioscavengers.  Finally, 
low molecular stoichiometric scavengers could be an eco-
nomic alternative to enzyme-based stoichiometric scaven-
gers. Several serine- and tyrosine-containing hexapeptides 
from a random library of peptides have been selected, be-
cause they react with a fluorescent analogue of sarin (Lan-
dry and Deng, 2006; Deng et al., 2008).
5 . CATALyTIC BIOSCAVENGERS AGAINST OPS
As said, the detoxification of OPs involves the hydrolysis 
of the phosphoester bond by organophosphorus acid anhy-
dride hydrolases (OPAH), also called phosphotriesterases 
(Pte), or oxidation to less toxic compounds by degrading 
their alkyl/aryl chain. though works on catalytic antibod-
ies (Vayron et al., 2000; Jovic et al. 2005; reshetnyak et al., 
2007) have made some progress, the re-design and engi-
neering of enzymes capable of degrading OPs is the most 
promising research field. these enzymes could be used as 
catalytic bioscavengers for prophylaxis and treatment of 
OP poisoning, for topical protection (Fisher et al., 2005), and 
for the decontamination of skin, mucosa and open wounds 
(Lejeune and russell, 1999; Gill and Ballesteros, 2000). Im-
mobilized OPAH in bioreactors can be used for the decon-
tamination of water (Simo et al., 2008), as well as genetically 
engineered bacteria producing OPAH can be introduced in 
water effluents of decontamination units for the purifica-
tion of contaminated water before recycling or washing up 
in the environment (chen and Mulchandani, 1998).
5 .1 . REquIREMENT FOR AN ENzyME TO BE AN EFFICIENT 
CATALyTIC BIOSCAVENGER AGAINST OPS
there are several general requirements for the use of en-
zyme-degrading OPs as medical countermeasures against 
OP poisoning. enzymes must have a wide spectra of activity, 
and ideally, enantioselectivity for toxic stereoisomers. their 
mass production under GMP conditions must be realizable 
at a reasonable cost. Long-term storage without activity loss 
must be possible under field conditions. conformational sta-
bility can be optimized by chemical modification or the addi-
tion of stabilizers. 
Other requirements depend on the way of administra-
tion, the delivery system or galenic formulation of enzymes. 
For parenteral administration, it must be remembered that 
the toxicant concentration in blood, [OP], even in the most 
severe cases of poisoning, is always very low, well below 
the Km of the enzyme for OP substrates. So, hydrolysis 
of OP in blood is pseudo first-order (Masson et al., 1998): 
v = kcat/Km
.[e].[OP]. the product of the bimolecular rate 
constant (kcat/Km) and enzyme active site concentration ([e]) 
is the pseudo first-order rate constant. thus, the higher the 
catalytic efficiency (kcat/Km), the lower the dose of enzyme 
to be administered for cleaning the blood of toxic molecules 
in a very short time (t). the catalytic efficiency of enzymes 
can be increased by several orders of magnitude by mu-
tagenesis or chemical engineering (Griffiths and tawfik, 
2003; Hill et al., 2003). the enzyme concentration in blood 
needed to drop [OP] to a non-toxic concentration in time, t, 
is [e] = X/(kcat/Km).
 
X is the factor by which [OP] is reduced 
(X= Ln[OP]0/[OP]t) (Masson et al., 2008). therefore, the 
second constraint is to maintain the bioscavenger concen-
tration, [e], in the blood as high as possible for a long time. 
[e] is controlled by the enzyme pharmacokinetics and/or 
the frequency of injections. Bioavailability and the biologi-
cal stability of injected stoichiometric or catalytic bioscav-
engers are important issues. Increasing the size of the en-
zyme by polymerization, conjugation to albumin, reducing 
the microheterogeneity of glycans, and chemical modifica-
tions of solvent-exposed surfaces improve the biological life 
of injected bioscavengers. Fast clearance of glycoproteins is 
often due to glycosylation defects. these can be correct-
ed by chemical modifications.  Pharmacokinetic studies of 
glycoproteins injected to animals showed that the enzyme 
clearance depends on sialylation of glycans.  rapid elimina-
tion of asialoglycoproteins from the blood stream is due to 
their capture by galactose receptors located on the surface 
of hepatocytes. Galactose is the residue that precedes sialic 
acid at the terminus of complex glycans.  Pharmacokinetic 
studies with natural and recombinant ches confirmed the 
importance of sialic acid residues ending glycans (Kronman 
et al., 1995; Saxena et al., 1998; cohen et al., 2007; Kronman 
et al., 2007). It was found that the half-life, t1/2, is inversely 
proportional to the number of unoccupied attachment sites 
of sialic acid (Kronman et al., 2000). to increase t1/2 of ad-
ministered recombinant ches, all galactosyl residues have 
to be sialylated.  Full sialylation of recombinant enzymes 
can be achieved by the selection of an appropriate expres-
sion system (chitlaru et al., 1998) capable of synthesizing 
glycans similar to natural human glycoprotein glycans and 
adding inhibitors of sialidase in the cell culture medium. 
co-expression of human Ache and sialyltransferase in 
HeK 293 cells was found to produce fully sialylated recom-
binant enzyme (Kronman et al., 2000).  Alternatively, in 
vitro polysialylation of purified enzymes is possible with a 
sialyltransferase or by using a chemical method (Gregori-
adis et al., 1999).  PeGylation was also proved to be an ef-
fective chemical modification for increasing the circulatory 
half-life of administered recombinant ches (cohen et al., 
2006, 2007; Huang et al., 2007; Kronman et al. 2007; Mazor 
et al., 2008; chilukuri et al., 2008). recently, a 150 kDa re-
combinant fusion protein human albumin-human Bche 
showed substantially improved pharmacokinetics when 
administered to juvenile pigs, t1/2 ≈ 32h against ≈ 3h for re-
combinant 70%-tetrameric Bche (Huang et al., 2008).
Immunotolerance of injected enzymes is a major issue. 
For instance, bacterial enzymes are not suitable for use in 72 | ActA nAturAe |  № 1 2009
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humans, but conjugation to dextran, PeG or inclusion in na-
nocontainers can reduce antigenicity and slow down clear-
ance.
enzymes in skin and eye lotions, immobilized in foams 
and on tissues for skin and eye decontamination (Gordon 
et al., 2003; Simo et al., 2008), or in topical skin protectants 
(Braue et al., 2002), act under conditions where local [OP] 
can be very high. In this case, enzyme reaction order in 
[OP] tends to zero, so that the reaction rate is close to maxi-
mum velocity, kcat.[e]. thus, under these conditions, effi-
ciency depends on the concentration and catalytic constant 
of the enzyme. therefore, for external use, enzymes have 
to display high molecular catalytic activity and be high-
ly concentrated.  co-immobilization of different enzymes 
could be an easy way to extend the spectra of agents to be 
degraded. this should allow simultaneous detoxification of 
different agents. Indeed, exposure to multiple agents has 
to be considered. In particular, in asymmetric conflicts, es-
chatological and criminal terrorism acts, the most extreme 
scenario has to be anticipated. 
5 .2 . POTENTIAL ENzyMES 
Cholinesterases - OPs may be regarded as hemi-substrates 
of ches (Fig. 2). When the enzyme reacts with carboxyl-es-
ters, it is transiently acylated, the acyl group being rapidly 
displaced by a water molecule. On the contrary, with phos-
phyl-esters, the stereochemistry of the phosphyl-enzyme 
intermediate restricts the accessibility of water to the phos-
phorus atom. thus, the spontaneous hydrolysis of the phos-
phylated enzyme is very slow or even impossible. Jarv pos-
tulated that the introduction of a second nucleophile pole 
in the active center could activate a water molecule. this 
water molecule could subsequently attack the phosphorus 
atom on the back face, leading to breakage of the P-serine 
bond (Jarv, 1989). the resolution of the three-dimensional 
structure of Topedo californica Ache (Sussman et al., 1991) 
opened the way to the rational re-design of ches. thus, the 
possibility to convert ches into OP hydrolases (OPHs) was 
hypothesized.  Human Bche was chosen because its active 
center is larger (500 Å3) than that of Ache (300 Å3) and it is 
less stereospecific. Molecular modeling based on the struc-
ture of Torpedo Ache was used for making mutants of hu-
man Bche. the second nucleophile pole was created in the 
oxyanion hole of the active center where a glycine residue 
was replaced by a histidine. this first mutant, G117H, was 
capable of hydrolyzing paraoxon, sarin, echothiophate and 
VX (Millard et al., 1995; Lockridge et al., 1997). However, 
it was irreversibly inhibited by soman, because “aging” 
of the conjugate was faster than dephosphonylation. the 
mechanism of aging, i.e. dealkylation of an akyl chain on 
the phosphorus atom, is almost completely elucidated (cf. 
Fig. 2). this reaction involves a carbocationic transient that 
is stabilized by active site residues e197 and W82 and water 
molecules (Shafferman et al., 1996; Viragh et al., 1997; Mas-
son et al., 1999; nachon et al., 2005; Li et al. 2007).  Mutation 
of e197 into D, Q or G brought doun the rate of aging. As 
expected, the double mutant G117H/e197Q was capable 
of hydrolyzing soman (Millard et al., 1999). However, the 
catalytic activity of the double mutant was too slow to be 
of pharmacological interest.  
the discovery of a fly (Lucilia cuprina) resistant to OPs 
because it carries a mutated carboxylesterase (cae) at a po-
sition homologous to G117, i.e G137D, stimulated research 
on G117H-based mutants of Bche. though the OPAH 
activity of the G137D mutant is low, it is balanced by the 
abundance of the enzyme in insect organs (newcomb et al., 
1997).  Mice knockout for Ache and carrying the G117H 
mutant of human Bche were found to be less sensitive to 
OP than wild-type mice (Wang et al., 2004). though these 
mice express the G117H mutant in all organs, unlike the 
resistance of Lucilia cuprina, their resistance to OP can-
not be explained by the OP hydrolysis that is too slow, but 
rather by the hydrolysis of excess acetylcholine that accu-
mulates in cholinergic synapses.
More than 60 double or triple mutants of human Bche 
with mutated G117 (Schopfer et al., 2004) and mutants of 
human Ache and Bungarus fasciatus Ache were made us-
ing the same rationale (Poyot et al., 2006). For a review of 
these works, see Masson et al., (2008). none of the mutated 
ches was more active than the G117H mutant, and we pro-
vided evidence that mutations at position G117 cause dislo-
Figure 2: Inhibition of cholinesterases by OPs and reactivation of phos‑
phylated enzymes
After formation of reversible complex between ChE and OP (step 1), the 
active serine (esteratic site, E‑OH) is phosphylated and there is release 
of OP leaving group X (step 2). Phosphylated ChEs can be reactivated 
by nucleophilic agents, such as oximes (Pralidoxime, MMB4, Obidoxime, 
HI‑6, etc) used as antidotes in emergency treatment of OP poisoning 
(Lundy et al., 2006; Worek et al., 2007) (reaction 3); water is a too 
weak nucleophile for fast spontaneous reactivation of phosphylated 
ChEs. Phosphyl‑ChE conjugates may undergo a dealkylation (‘aging’) 
(Shafferman et al., 1996; Viragh et al., 1997; Masson et al., 1999; Li 
et al., 2007; Carletti et al., 2008), resulting in irreversibly inactivated 
(“aged”) enzyme (step 4). The dealkylation reaction can be very fast 
(t1/2 = 3 min at 37°C for human AChE phosphonylated by soman). At the 
moment, drug‑mediated reactivation of aged ChE is not possible.reVIeWS
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cation and loss of functionality of the oxyanion hole (Masson 
et al., 2007).   
However, computer-assisted design of new OPH mutants 
of ches is conceivable using a new approach called “intelli-
gen” directed mutagenesis design based on the simulation of 
transition states. As mentioned, this approach was success-
fully applied for making Bche mutants that hydrolyze (-)
cocaine at a high rate. Simulation of dephosphylation transi-
tion states is expected to indicate how to optimize interac-
tions favouring productive crossing of the dephosphylation 
energetic barrier. Directed evolution of ches could be an al-
ternative to computer-based methods. However, functional 
expression of ches is difficult in yeast (Durova et al., unpub-
lished results) and has failed in bacteria so far. 
certain che mutants sensitive to OPs not susceptible to 
aging are fully reactivatable by oximes.  thus, che mutants 
associated with oxime reactivators act as pseudo-catalysts 
in displacing the OP moiety bound to the enzyme. these en-
zyme-reactivator-coupled systems could lead to a new fam-
ily of pseudo-catalytic bioscavengers  (taylor et al., 2007; 
Kovarik et al., 2007,2008; Mazor et al., 2008). 
Phosphotriesterases - enzymes that catalyse the hydroly-
sis of phosphoester bonds in OPs are ubiquitous, e.g. a pro-
lidase named organophosphorus acid anhydrolase (OPAA) 
was identified in a strain of Alteromonas (cheng et al., 1999), 
a diisopropylfluorophosphatase (DFPase) is abundant in the 
squid Loligo vulgaris, and paraoxonase-1 (POn1) is present 
in human plasma. Bacterial enzymes called phosphotrieste-
rases (Pte; ec 3.1.8.1), or sometimes organophosphorus 
hydrolases (OPH), organo-phosphate-degrading enzymes 
(OpdA), show preference for OP compounds with P-O or 
P-S bonds. Pte are members of the amidohydrolases super-
family (Seibert and raushel 2005).
Bacterial phosphotriesterases  - Phosphotriesteras-
es (Pte; ec 3.1.8.1) are encoded by the organophosphate 
degradation (opd) gene found in Pseudomonas diminuta, 
Flavobacterium sp., and Agrobacterium radiobacter. Genes 
similar to opd were also found in Archaea (Merone et al., 
2005). Pseudomonas diminuta Pte is a 72 kDa dimeric bi-
metallic enzyme with Zn2+ involved in catalysis (carletti et 
al., in press). Substitution of Zn2+ ions in the active site with 
Mn, co, ni, or cd ions results in the almost full retention 
of catalytic activity. Following the first determination of 
the three-dimensional structure of P. diminuta Pte (Ben-
ning et al., 1994), a series of crystal structures, kinetic, and 
spectroscopic experiments were described. Pte cataly-
sis proceeds via a Sn2 mechanism with the formation of a 
pentacoordinated transition state. the mechanism of the 
nucleophilic attack and enzyme regeneration are largely 
debated, and the functional roles of divalent metal cati-
ons and amino acids in the active centre are not yet fully 
understood (Aubert et al., 2004; Samples et al., 2007; chen 
et al., 2007; Wong and Gao 2007; Jackson et al., 2008). re-
cently, the structure of SsoPox (a hyperthermopholic Pte 
from the archeon Sulfolobus solfataricus) provided new in-
formation that led to a refined mechanism (elias et al. 2008; 
Del Vecchio et al., 2009). no natural substrate of Pte has 
yet been identified (Ghanem and raushel, 2005) and Pte 
is thought to have evolved from  lactonase (Afriat et al., 
2006), the Pte activity being considered as a promiscuous 
activity (elias et al., 2008). Whereas the catalytic efficiency 
of Pte for paraoxon, the best substrate identified so far, is 
approaching the diffusion-controlled limit, it is slow against 
OP nerve agents (table 1). Meanwhile, directed evolution 
of Pte showed that only 3 amino acid changes dramati-
cally enhanced the catalytic efficiency for an analogue of 
soman by ~3 orders of magnitude (Hill et al., 2003). 
numerous studies have highlighted the potential of Pte 
for decontamination, skin protection, and biosensor detec-
tion of OP (Lejeune and russell, 1999; Gill and Ballesteros, 
2000; Létant et al., 2005; Ghanem and raushel, 2005; Kar-
nati et al., 2007). Administration of Pte before or after OP 
exposure was shown to improve pre-treatment and current 
treatment of OP poisoning (Doctor and Saxena, 2005). OpdA 
was shown to improve survival after poisoning by highly 
toxic OP pesticides (Bird et al., 2008).  to prevent abnormal-
ly fast pharmacokinetics and/or an immunological response 
of injected bacterial enzymes, Pte can be PeGylated (Jun et 
al., 2007, 2008) or encapsulated. First attempts at using Pte 
encapsulated within sterically stabilized liposomes were 
promising, providing protection to rats from multiple LD50 of 
OP pesticides (Petrikovics et al., 2004). Alternatively, blood 
detoxification could be achieved by extracorporeal circula-
tion through a hollow fiber cartridge coated with immobi-
lized Pte (Masson et al., unpublished results).  
Ptes possibly could also be used for skin protection as ac-
tive components of topical skin protectants (tSPs) or cova-
lently coupled to the cornified layer of epidermis (Parsa and 
Green, 2001). thermostable Ptes from thermophilic bac-
teria (Merone et al., 2005; elias et al., 2008; Del Vecchio et 
al., 2009) or mutated/evolved highly stable enzymes from 
mesophilic bacteria are promising for topical protection and 
decontamination.  Pte was also entrapped in additives for 
latex coating of biodefensive surfaces. Such Pte-based ad-
ditives for paints and coatings were shown to retain catalytic 
parameters and the stability of the enzyme (McDaniel et al., 
2006). For the environment's decontamination and remedia-
tion, an alternative approach, phytodegradation by trans-
genic plants (e.g. tobacco) expressing a bacterial Pte, has 
been considered as a potentially low-cost, safe, and effective 
method (Wang et al., 2008).
Human paraoxonase-1- POn1 is a 45 kDa glycosylated 
calcium-dependent enzyme expressed mainly in the liver 
and exclusively bound to high-density lipoproteins (HDL), in 
association with other apolipoproteins (Fig. 3). POn1 shows a 
genetic polymorphism; the most prominent determines the 
Q192r allozyme that has a substantial impact on POn1 ac-
tivity with arylesters and OPs (Smolen et al., 1991) (table 1). 
chemical modification and site-directed mutagenesis studies 
have identified essential amino acid residues for the activi-
ties of POn1 (Josse et al., 1999; Yeung et al., 2004; Kherson-
sky and tawfik 2006; Amitai et al., 2007; tavori et al., 2008; 
Hu et al., 2009).
Attempts at solving the three-dimensional structure of 
human POn1 have failed so far. However, molecular mod-
eling (Fokine et al., 2003; Yeung et al., 2004) and the crys-
tal structure of a hybrid mammalian recombinant POn1 
variant obtained by directed evolution (rPOn1) (Harel et 
al., 2004) showed that POn1 is a six-bladed β-propeller 
protein similar to Loligo vulgaris DFPase (Katsemi et al., 74 | ActA nAturAe |  № 1 2009
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2005). the catalytic mechanism of DFPase was recently 
described (Blum et al., 2006). confirmation of a similar 
mechanism for human POn1 activity would considerably 
help to design more active POn1 mutants. the active site 
lid of POn1 is in close contact proximity to the area pre-
sumed to mediate binding of POn1 to HDL. It has been 
suggested that the hydrophobic n-terminus of POn1 me-
diates its anchoring to HDL, but the precise mode of bind-
ing of POn1 to HDL, as well as of other HDL-associated 
proteins, is still unknown.
As a naturally occurring plasma enzyme, human POn1 is 
the most promising catalytic bioscavenger candidate for pre-
treatment and therapy of OP poisoning (La Du, 1996; rochu 
et al., 2007a). thus, POn1 is the focus of intensive research to 
improve its efficacy and functionalization. to provide a val-
uable medical countermeasure against intoxication by nerve 
agents, the catalytic efficiency of POn1 has to be enhanced 
by only 1 or 2 orders of magnitude. Mutants of rPOn1 ob-
tained by directed evolution and exhibiting enhanced OP-
hydrolase activity (Amitai et al., 2006) suggest this goal can 
be reasonably achieved soon. However, the instability of 
these mutants could impinge on their biotechnological de-
velopment. Plasma POn1 works in a complex and dynamic 
milieu, HDL particles that include durably or transiently up 
to 90 associated proteins (Vaisar et al., 2007). thereby, POn1 
requires association to apolipoprotein partners to retain its 
stable active conformation (James and Deakin, 2004; Gaidu-
kov and tawfik, 2005).
Table 1.  Catalytic efficiency (kcat/Km, M‑1 min‑1) of different natural and engineered OP hydrolases towards different OPs
Source of enzyme Paraoxon DFP Tabun Sarin Soman gF Echothiophate VX
Human POn1 Q192 6.8 x 105 [a] 4 x 104 [b] 9.1 x 105 [c] 2.8 x 106 [c] +   [d]
Human POn1 r192 2.4 x 106 [a] 7 x 104 [c] 2.1 x 106 [c] +   [d]
Human rPOn1 in 293t 6.2 x 105- 4.1 x 106 [e]
Mammalian rPOn1 G3c9  7.2 x 105 [f]
Mammalian rPOn1 V346A 8.7 x 104 [g] 3.6 x 105[g]
Human Bche G117H 5.7 x 103 [h] 5.2 x 103 [h] 1.6 x 102  [i] - 1 x 104 [h]  1.5 x 103 [i]
Blowfly cae G117D 2 x 105 [j]
B. fasciatus Ache  HQt     64 [h] 7.6 x 102 [h] 24 [h]
Loligo vulgaris DFPase 7.8 x 107 [k] 2.4 x 106 [k] 2.4 x 106[k] 0  [k]
P. diminuta OPAH 2 x 109 [l] 5.8 x 108 [m] 4.8  x 106 [n] 6 x 105 [n] 5 x 103 [o] 4 x 104 [p]
Alteromonas sp. JD6.5 OPAA 4.6 x 107[q] 14.6 [r]
Alteromonas sp. JD6.5 cloned 5.8 x 106  [r] 1 x 107  [r] 6.2 x 107 [r]
Alteromonas  undina 21.8 [s] 30.4 [s] 1.6 x 102 [s] 1.3 x 102 [s]
nG108-15 hybrid cells  2.5 x 103 [t]
[a] Smollen et al., 1991; [b] Masson et al., 1998; [c] Davis et al., 1996;  [d] C.A. Broomfield, unpublished result; [e] Yeung et al., 2008, with the 
four soman stereoisomers; [f] Harel et al., 2004; [g] Amitai et al., 2006;  [h] Poyot et al., 2006; [i] Lockridge et al.,  1997; [j] Newcomb et al., 1997; 
[k] Hartlieb and Ruterjans 2001; [l] Kuo et al., 1997; [m] Lai et al., 1995; [n] Dumas et al., 1990; [o] Hoskin et al., 1995; [p] Rastogi et al., 1997; [q] 
Cheng et al., 1999; [r] Cheng et al., 1994; [s] DeFranck et al., 1993; [t] Ray et al., 1988.reVIeWS
 № 1 2009  | ActA nAturAe | 75
Human Phosphate Binding Protein (HPBP), an apolipo-
protein that binds inorganic phosphate in blood was discov-
ered recently.  Its three-dimensional structure and complete 
amino acid sequence were solved (Morales et al., 2006; Die-
mer et al., 2008). the conditions to separate HPBP and POn1 
in vitro indicate that HPBP is tightly associated with POn1 
(renault et al., 2006). Moreover, stabilization of the active 
form(s) of human POn1 by HPBP shows that HPBP acts as 
a functional chaperone (rochu et al., 2007b,c; cléry-Barraud 
et al., 2009).
We are attempting at co-crystallization of the POn1-
HPBP complex. For this, the first step was to construct a 
hybrid gene for co-expression of HPBP and POn1 in E. 
coli. For this purpose, a HPBP gene was synthesized from 
its amino acid sequence. co-expression, aimed to favour 
correct folding of active POn1 and stabilization of the ac-
tive functional conformation of the enzyme, is expected to 
provide a crystallizable POn1-HPBP complex. Finally, dif-
fractable crystals of the complex are assumed to provide a 
three-dimensional structure of natural human POn1. this 
crucial phase will be the first step of the staircase, leading 
to the development of stable human POn1 mutants with 
enhanced catalytic efficiency against OPs. the fact that 
functional expression of human POn1 seems to be feasible 
(Stevens et al. 2008) would simplify the biotechnology of 
POn1 and open new perspectives.
Other enzymes - Other hydrolases are involved in biodeg-
radation of OPs, such as organophosphorus acid anhydro-
lases (OPAA; ec 3.1.8.2) and organophosphate-degrading 
agents (OpdA) or prolidases (ec 3.4.13.9). Prolidases were 
first isolated from halophilic bacteria (Alteromonas ha-
loplanktis and A. sp. JD6.5).  Prolidase from A. sp. JD6.5 is 
an OPAA that displays the highest known activity against 
soman (kcat = 3100 s-1), but it is inactive against VX (cheng 
et al. 1999).  OpdA was incorporated as the active ingredi-
ent of Landguard™ OP-A, a formulation developped for the 
treatment of water run-off, equipment rinsing and soil de-
contamination (Dawson et al., 2008). Whilst these applica-
tions are focussed on agricultural and remediation markets, 
modifications required for nerve agent detoxification will be 
relatively minor, as the enzyme can be applied in powder, 
liquid or matrix-bound forms.  
A prolidase was also isolated from human liver. this 
prolidase displays a high catalytic activity against soman 
and exhibits sequence homology with the Aleromonas ha-
loplanktis prolidase (Wang et al., 1998). Human prolidase 
has been cloned and expressed in Sacharromyces cerevisiae 
and Pichia pastoris, and it appears to be one of the most 
interesting OP-degrading enzyme for protection against 
nerve agents (Wang et al., 2005; Wang et al., 2006). the 
newly discovered human cytosolic aminopeptidase (AMPP; 
ec 3.4.11.9) could also be a valuable catalytic bioscavenger 
against organophosphates and organophosphonates (Hsu et 
al., 2008).
Laccases (ec 1.10.3.2) are fungal phenol oxidoreduct-
ases that have been used for detoxification of numerous 
xenobiotics (richardt and Blum, 2008). the laccases from 
Pleurotus ostreatus and Chaetomium thermophilium were 
found to rapidly degrade VX and Vr in the presence of 
2,2’-azinobis(3-ethylbenzthiazoline-6-sulfonate (ABtS) as 
the mediator (Amitai et al., 1998). We found that laccases 
from Trametes versicolor and Coriolopsis polyzona with 
ABtS display similar properties against V agents (trovas-
let et al., unpublished results). the heme-containing chlo-
roperoxidase (ec 1.11.1.X) from Caldaromyces fumago, with 
peroxide as co-substrate, is another efficient VX-degrading 
enzyme (Amitai et al., 2003).
these enzymes are of interest for the destruction of 
chemical weapons stockpiles, soil remediation, the decon-
tamination of materials, protective equipments, and water 
polluted by pesticides and nerve agents (russel et al., 2003). 
In particular, phosphorothiolates such as VX are relatively 
resistant to Pte. thus, oxidative cleavage of the P-S bond 
could be achieved by oxidases like laccases. these enzymes 
could be used associated with other OP-degrading enzymes 
for skin decontamination and topical skin protection. though 
no work has been performed on the combined action of 
oxidases and hydrolases, oxidation of P-bonded alkyl/aryl 
chains by oxidases is expected to alter enantioselectivity of 
Pte for parent OPs, and therefore to improve the efficiency 
of catalytic bioscavengers.
Figure 3: Scaled schematic representation for a PON1‑containing HDL 
particle 
HDL is ~ 10 nm‑diameter sphere with a non‑polar core of cholesteryl‑
esters and triglycerides encapsulated in a monolayer of amphipathic 
α‑helical apolipoproteins and phospholipids. Among multiple HDL‑
associated proteins involved in lipid metabolism, complement regulation, 
acute‑phase response and proteinase inhibition (Vaisar et al., 2007), 
some of them, durably or transiently associated to PON1‑containing HDL 
and described as having a propensity to contaminate purified PON1 frac‑
tions, are shown. 76 | ActA nAturAe |  № 1 2009
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enzymes that degrade OPs have been isolated from hu-
mans, different animal species, fungi and bacteria.  Identi-
fication and isolation of new natural enzymes, in particular 
in insects resistant to OP pesticides and among secondary 
targets of OPs in humans is an active field of research. 
Also, potential extremozymes have been discovered in ha-
lophilic, thermophilic and piezophilic bacteria and other 
extreme environments (Merone et al., 2005; Feerer et al., 
2007). All these enzymes can be purified from their natu-
ral sources. However, production of natural enzymes free 
of infectious agents under GMP is expensive.  thus, suit-
able biopharmaceuticals are mostly recombinant enzymes. 
these enzymes can be produced in prokaryotic expression 
systems (E. coli), eukaryotic expression systems (yeast, in-
sect, mammalian cell cultures), transgenic animals (worm, 
rabbit, goat), transgenic plants (tomato, potato, tobacco), 
and also acellular biosynthetic systems. current research’s 
goal in protein engineering is to improve mass production 
of stable enzymes at low cost.  
Improvement of in vitro and in vivo catalytic properties 
of cocaine hydrolases and OPAH-degrading nerve agents 
and pesticides is the main issue.  Improvement of thermody-
namic stability for long-term storage in solution or in lyophi-
lized forms, and in vivo operational stability, improvement 
of immuno-tolerance and bioavailability are other major 
goals.  Molecular modeling and transition state simulations, 
site-directed mutagenesis and directed-evolution approach-
es in combination with chemical modifications and medium 
manipulations have been successfully used to improve the 
properties of selected enzymes (Bershtein and tawfik, 2008). 
Lastly, pharmacokinetic, toxicokinetic and immunological 
studies on animal models, and then on volunteers will vali-
date enzymes of interest.  Multiple enzymes will be associ-
ated in active topical skin protectants and decontamination 
tools.  Soon, catalytic bioscavengers are going to take a place 
among medical countermeasures for prophylaxis and treat-
ment of acute OP poisoning and treatment of cocaine over-
dose.
In the future, gene therapy could be considered to chal-
lenge OPs. this strategy will offer the possibility of transi-
tory production of humanized OP-degrading enzymes in the 
body. Promising results have already been obtained with 
human Ache and Bche (Li et al., 2006; chilukuri et al. 2008) 
and human POn1 (conwan et al., 2001; Fu et al., 2005; Brad-
shaw et al., 2005; Miyoshi et al., 2007; Guns et al., 2007; Zhang 
et al. 2008).  Again, the use of mutated POn1 genes encod-
ing for an enzyme with high OPH activity against pesticides 
and nerve agents appears to be the most promising ap-
proach.  Several studies, using different gene-delivery vec-
tors in mice, showed that the level of POn1 in plasma was 
increased.  High POn1 levels slowed and even prevented the 
entry of OP into the brain and reduced atherosclerosis signs 
(conwan et al., 2001; Fu et al., 2005; Bradshaw et al., 2005; 
Guns et al., 2008).  Local delivery of the POn1 gene using the 
Sendai virus vector inhibited neonatal hyperplasia after arte-
rial balloon-injury in rabbits fed a high-fat diet (Miyoshi et 
al., 2007).  transfer of the human POn1 Q gene in mice led to 
efficient expression of the enzyme that was capable of pro-
tecting the liver against oxidative stress (Zhang et al. 2008). 
thus, enhanced expression of POn1 by gene therapy could 
be beneficial to the different functions of the enzyme. Mean-
while, the multiple and defectively identified POn1 activi-
ties make it apparent that strategy for repetitive adminis-
tration of high concentration of POn1 in humans must be 
undertaken with caution. 
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